Nivolumab

Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test

Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test

5 days ago   |   Xconomy   |   2 articles

A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers. On Tuesday the company...
Read more ...

Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal

Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal

1 month ago   |   Xconomy

Neon Therapeutics closed 2019 by curtailing its cancer vaccine programs and laying off 24 percent of its workforce, part of a corporate restructuring aimed at finding a new...
Read more ...

Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck

Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck

2 monthes ago   |   Xconomy

A Roche immunotherapy has won an additional FDA approval as a first-line treatment for non-small lung cancer, bolstering the product's competitive stance versus one from Merck...
Read more ...

Bio Roundup: MedCo's Pricing Plan, Vertex's Gamble, uBiome Undone

Bio Roundup: MedCo's Pricing Plan, Vertex's Gamble, uBiome Undone

5 monthes ago   |   Xconomy

Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much...
Read more ...

Bio Roundup: Leiden's Exit, Depression Data, a New Pricing Bill & More

Bio Roundup: Leiden's Exit, Depression Data, a New Pricing Bill & More

6 monthes ago   |   Xconomy

What will the legacy be of Jeff Leiden, the longtime CEO of Vertex Pharmaceuticals? Vertex surprised Wall Street this week by announcing Leiden's seven-year run will end next...
Read more ...

Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck

Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck

6 monthes ago   |   Xconomy

Bristol-Myers Squibb this afternoon revealed yet another setback for its cancer immunotherapy nivolumab in lung cancer, boosting the outlook for rival Merck. The New York...
Read more ...

Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More

Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More

7 monthes ago   |   Xconomy

It was a busy week. If we had to choose a theme, it was all about getting together. Two huge drug companies, AbbVie and Allergan, said they'd be better as one. Two more huge...
Read more ...

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

8 monthes ago   |   Xconomy

The American Society of Clinical Oncology meeting in Chicago has wrapped up for another year. Last week, we featured two stories that you wouldn't find at the ASCO frenzy...
Read more ...

Can Tiny Drug Doses Fight the Most Vicious Cancer?

Can Tiny Drug Doses Fight the Most Vicious Cancer?

8 monthes ago   |   Xconomy

When the brain goes bad, modern medicine is often powerless to help. That's the case for Alzheimer's disease, where drug after drug has failed, and the only approved treatments...
Read more ...

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation

8 monthes ago   |   BMC Bioinformatics

Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Invetx Fetches $15M to Develop Biologic Drugs for Man's Best Friend

Invetx Fetches $15M to Develop Biologic Drugs for Man's Best Friend

Veterinarians have a saying that a cat is not a small dog, says Invetx CEO Juergen Horn. Obviously, a dog of any size isn't the same as a human. But Horn, a veterinarian, says... Read more ...

Lundbeck's Alder Bio Bet Pays Off With FDA Approval of Migraine Drug

Lundbeck's Alder Bio Bet Pays Off With FDA Approval of Migraine Drug

A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals won FDA approval on Friday. The drug, eptinezumab , is... Read more ...

Bonus Episode of TBD: Europe's New AI Strategy

Tech Policy is a rapidly evolving field, and from time-to-time we hope to release these bonus episodes to give you some insight into things as they're happening in real-time... Read more ...

Arima Genomics Completes Series A Financing

SAN DIEGO--Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and... Read more ...

Viking Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ - Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and... Read more ...

Molecular characterization and overexpression analyses of secologanin...

Abstract Camptothecin is a high-value anti-cancerous compound produced in many taxonomically unrelated species. Its biosynthesis involves a complex network of pathways and a... Read more ...

Modulation of the Purine Pathway for Riboflavin Production in Flavinogenic...

Riboflavin is an indispensable nutrient for humans and animals, since it is the precursor of the essential coenzymes FMN and FAD, involved in variety of metabolic reactions... Read more ...

A Critical Review of Genome Editing and Synthetic Biology Applications in...

Being the green gold of the future, microalgae and cyanobacteria have recently attracted considerable interest worldwide, for they can be used to produce different kinds of... Read more ...

Biodegradation of penicillin G from industrial bacteria residue by...

An efficient biodegradation-strengthening approach was developed to improve penicillin G degradation from industrial bacterial residue in an expanded bed adsorption bioreactor... Read more ...

More clues for how the monkeyflower got its spots

The monkeyflower, or Mimulus, though possessing a relatively simple genome is able to produce a stunning array of pigmentation patterns. A team of researchers is one step... Read more ...